Wire
Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable Sept. 10 to Holders of Record Aug. 14
Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable Sept. 10 to Holders of Record Aug. 14
$LLY
Eli Lilly and Company
$LLYNYSEHealthcare
198 stories mentioning Eli Lilly and CompanyUpdated 2d ago
Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.
What are analysts saying about Eli Lilly and Company?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on Eli Lilly and Company?
Sectors
Sector Update: Healthcare Stocks Ease Late Afternoon
Healthcare stocks eased late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) also dropped 0.2%.In corporate news, Eli Lilly (LLY) acquired 4E Therapeutics, a neuroscience firm creating chronic-pain treatments. Lilly shares fell 1%.CAMP4 Therapeutics (CAMP) shares jumped 6.1% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares eased 0.1%.Oncolytics Biotech (ONCY) shares climbed 11% after the company received a US patent covering the pelareorep manufacturing process into 2044.
$CAMP$GSK$LLY$ONCY
Sectors
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.2%.The iShares Biotechnology ETF (IBB) was down 0.2%.In corporate news, GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares rose 0.3%.Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, within the next few months, Reuters reported, citing Chief Executive Mike Doustdar. According to the report, Eli Lilly (LLY) submitted a marketing application in China for its oral obesity drug late last year, putting the company ahead of Novo in the race to launch a weight-loss pill in the country. Novo shares were down 0.3%, and Lilly was 0.1% lower.Oncolytics Biotech (ONCY) shares jumped past 10% after it said Tuesday it has received a US patent covering the pelareorep manufacturing process into 2044.
$GSK$LLY$NVO$ONCY
Wire
Eli Lilly Acquires 4E Therapeutics
Eli Lilly (LLY) has acquired 4E Therapeutics, a neuroscience firm creating chronic pain treatments, 4E Therapeutics said Tuesday.The company said its lead compound, 4ET1103, showed a favorable safety profile in a phase 1 study.Financial terms were not disclosed.Price: $1124.39, Change: $-4.96, Percent Change: -0.44%
$LLY
Wire
CMS Proposes Permanent Framework for Medicare Drug Price Negotiation Program
The Centers for Medicare & Medicaid Services on Friday proposed a rule to establish a permanent regulatory framework for the Medicare Drug Price Negotiation Program beginning with the 2029 price applicability year, transitioning from implementation through annual guidance to codified regulations.The proposal would govern future negotiations and renegotiations for high-cost, single-source drugs covered under Medicare Part D and Part B. CMS said it will select up to 20 additional negotiation-eligible drugs for the fourth cycle of negotiations and future cycles of the program.The rule also proposes a temporary pricing floor for certain small biotech drugs in 2029 and 2030.CMS said it has negotiated prices for 25 high-expenditure drugs during the program's first two years. Maximum fair prices for the first 10 selected drugs took effect Jan. 1, 2026.Price: $236.56, Change: $-4.31, Percent Change: -1.79%
$ABBV$JNJ$LLY$MRK$NVO
Insider Trading
Eli Lilly Insider Sold Shares Worth $2,876,925, According to a Recent SEC Filing
Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company, on June 10, 2026, sold 2,500 shares in Eli Lilly (LLY) for $2,876,925. Following the Form 4 filing with the SEC, Yuffa has control over a total of 29,804 common shares of the company, with 29,804 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/59478/000182600126000006/xslF345X05/wk-form4_1781209410.xml
$LLY
Sectors
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 3%.In corporate news, Adial Pharmaceuticals (ADIL) shares surged 45% after it said Thursday it has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases.Novartis (NVS) shares gained 4.2% after the company said a phase 1/2 trial of its experimental treatment del-brax met both primary and key secondary endpoints in people with facioscapulohumeral muscular dystrophy.Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition. Novo shares rose 2.8%.Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported, citing the Business Group on Health, a policy research group for large employers. Lilly shares were up 2.9%.
$ADIL$LLY$NVO$NVS
Sectors
Sector Update: Healthcare Stocks Rise Thursday Afternoon
Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.5%.The iShares Biotechnology ETF (IBB) climbed 1.9%.In corporate news, Novartis (NVS) shares gained 2.9% after the company said a phase 1/2 trial of its experimental treatment del-brax met both primary and key secondary endpoints in people with facioscapulohumeral muscular dystrophy.Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition. Novo shares rose 1.2%.Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported, citing the Business Group on Health, a policy research group for large employers. Lilly shares were up 1.5%.
$LLY$NVO$NVS
Wire
Market Chatter: Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027
Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported Thursday, citing the Business Group on Health, a policy research group for large employers.Around 10% of employers who now cover GLP-1 drugs for weight-loss said they are planning to drop that coverage next year, the report said, citing the policy research group.Novo Nordisk and Eli Lilly didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $43.51, Change: $+0.72, Percent Change: +1.68%
$LLY$NVO
Wire
Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027, Reuters Reports
Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027, Reuters Reports
$LLY$NVO
Sectors
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) added 1.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 1%, and Nuvalent surged 39%.Brookdale Senior Living (BKD) has reported May occupancy data in line with bullish comments by the company's management at a recent event and ahead of levels implied in RBC's model for Q2, RBC Capital Markets said in a note. Brookdale shares jumped past 8%.PTC Therapeutics (PTCT) shares climbed 3.3% after Citigroup upgraded the company's stock to buy and raised its price target to $108.Eli Lilly (LLY) signed a collaboration and licensing deal worth over $1 billion with AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.4%.
$BKD$GSK$LLY$NUVL$PTCT
Sectors
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.8%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.Eli Lilly (LLY) entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.5%.NeuroSense Therapeutics (NRSN) shares added 1% after it said Tuesday that it has been issued a patent by the Japan Patent Office for PrimeC, its lead drug candidate to treat amyotrophic lateral sclerosis.
$GSK$LLY$NRSN$NUVL
Wire
Jefferies Adjusts Eli Lilly Price Target to $1,350 From $1,330, Maintains Buy Rating
Jefferies Adjusts Eli Lilly Price Target to $1,350 From $1,330, Maintains Buy Rating
$LLY
US Markets
Eli Lilly Signs Alzheimer's Licensing Deal Worth Over $1 Billion With AlzeCure
Eli Lilly (LLY) shares were up early Tuesday as the drugmaker entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease.Under the terms of the deal, Lilly will pay $10 million upfront to AlzeCure, which will also be eligible for mid-single-digit royalties on sales, the Swedish company said. Development and commercial milestone payments could push the total value of the transaction above $1 billion, excluding royalties.Lilly's stock increased 1.1% in the most recent premarket activity.AlzeCure is developing Alzstatin ACD680, a gamma-secretase modulator, to reduce the production of the harmful amyloid-beta protein, which forms the building blocks of the amyloid plaques found in the brains of Alzheimer's patients, the company said."The Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid in the brain," AlzeCure Chief Executive Martin Jonsson said in a statement. "In the long term, these compounds may also serve as a preventive treatment to prevent the development of Alzheimer's disease."The deal requires approval from regulatory authorities in Sweden, according to AlzeCure."The agreement with Lilly is an important milestone for AlzeCure and Alzstatin," Jonsson said.Lilly didn't immediately respond to a request for comment by.Lilly recently announced that its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea. The company also announced that overweight or obese women taking the highest dose of its obesity pill Foundayo, or orforglipron, lost weight across all stages of menopause in late-stage trials.
$LLY
Sectors
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Johnson & Johnson (JNJ) eased 0.3% after the firm said it has agreed to buy cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 1%.Eli Lilly (LLY) shares rose 1.6% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.Tango Therapeutics (TNGX) surged 51% after the firm said initial results from its phase 1/2 trial of vopimetostat plus Revolution Medicines' daraxonrasib showed a six-month progression-free survival rate of 90% in people with pancreatic cancer.
$INCY$JNJ$LLY$TNGX
Sectors
Sector Update: Healthcare Stocks Decline Monday Afternoon
Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) fell 1%.In corporate news, Johnson & Johnson (JNJ) decreased 0.8% after the company said Monday that it has agreed to acquire cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 3%.Eli Lilly (LLY) shares rose 2.2% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.
$INCY$JNJ$LLY
Sectors
Sector Update: Healthcare
Healthcare stocks eased Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) was down 0.7%.In corporate news, Eli Lilly (LLY) shares rose 2.4% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.
$LLY
Wire
Top Midday Stories: US Weighs Financial Stakes in AI Firms; Google, Nvidia Turn to Intel as TSMC Struggles With Demand
All three major US stock indexes were up in late-morning trading Monday, after Iran's Ministry of Foreign Affairs said its military has ceased its strikes against Israel, though they could resume if Israeli operations in Lebanon continue.The US government is considering taking a financial stake in artificial intelligence companies, with President Donald Trump planning to meet with executives next week, news outlets reported late Friday, citing the president's comments aboard Air Force One.In company news, Alphabet's (GOOG, GOOGL) Google and Nvidia (NVDA) have turned to Intel (INTC) as a backup manufacturer for their most advanced processors as Taiwan Semiconductor Manufacturing (TSM) struggles to meet overwhelming demand, The Information reported Monday, citing four people with direct knowledge of the discussions. Google has placed an order for over 3 million Tensor Processing Units from Intel in 2028, the report said, citing two of the people. Nvidia hasn't placed an order with Intel, but its evaluating whether Intel technology can be used to make a processor that combines four graphics chips into a single unit, two of the people reportedly told The Information. Shares of Alphabet's Class C and Class A shares were both down 1.2% around midday. Nvidia shares were up 1%. Intel shares were up 12%, while TSM shares were up 3.5%.Eli Lilly (LLY) said Sunday that overweight or obese female patients reduced their body weight throughout all menopausal phases while using the maximum dose of its Foundayo medication in two medical trials. The first trial showed that pre-menopausal, perimenopausal and post-menopausal individuals dropped a maximum of 28 pounds, 30.4 pounds, and 28.2 pounds over 72 weeks, the company said. During the second study focusing on subjects with type 2 diabetes, patients in the same three physiological stages shed up to 23.4 pounds, 18.5 pounds, and 27.8 pounds, the company said. Separately, the company reported Saturday that additional phase 3 data showed that its investigational molecule retatrutide achieved substantial weight loss with meaningful improvements in obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes. Eli Lilly shares were up 2.6%.Amazon (AMZN) said Monday it signed a multibillion-dollar deal with Corning (GLW) to supply optical fiber, cable and connectivity products for its growing US data center network. Amazon shares were down 0.1%, while Corning shares were up 6.3%.SpaceX (SPCX) has attracted about $150 billion in investor demand for its initial public offering, about twice the $75 billion it aims to raise, Reuters reported Sunday, citing people familiar with the matter.Tango Therapeutics (TNGX) said Monday that initial results from its phase 1/2 trial of vopimetostat, an investigational PRMT5 inhibitor, in combination with Revolution Medicines inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer. Tango shares were up 47%.Campbell's (CPB) reported fiscal Q3 adjusted earnings Monday of $0.50 per diluted share, down from $0.73 a year earlier but above the FactSet consensus analyst estimate of $0.48. Fiscal Q3 net sales were $2.37 billion, down from $2.48 billion a year ago and below the FactSet consensus of $2.38 billion. Campbell's shares were down 1.2%.Price: $207.86, Change: $+2.76, Percent Change: +1.35%
$AMZN$CPB$GLW$GOOG$GOOGL$INTC$LLY$NVDA$TNGX$TSM
Commodities
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Chip Stocks Rebound
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively traded Invesco QQQ Trust (QQQ) advanced 0.9% in Monday's premarket activity, as semiconductor shares rebound from Friday's selloff.US stock futures were also higher, with S&P 500 Index futures up 0.8%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 1.4% before the start of regular trading.The New York Fed's inflation expectations report for May will be released at 11 am ET.In premarket action, bitcoin was up by 3.8%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.4% higher, Ether ETF (EETH) advanced 6.8%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated by 0.01%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.6%, while the Vanguard Industrials Index Fund (VIS) was up 0.8% and the iShares US Industrials ETF (IYJ) was inactive.Graham (GHM) stock was down more than 7% before the opening bell after the company reported lower fiscal Q4 adjusted net income.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 1.8%, and the iShares US Technology ETF (IYW) was 1.8% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.8%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 3.8%, while the iShares Semiconductor ETF (SOXX) rose by 4.1%.Nvidia (NVDA) shares were up more than 2% in premarket activity after dropping by 6.2% on Friday. The company will expand artificial intelligence infrastructure in South Korea, beginning with a 55-megawatt deployment at Naver's GAK Sejong data center. The chipmaker also closed a multi-year deal with SK hynix to design future generations of artificial intelligence memory hardware.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.2% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.8%. The iShares US Consumer Staples ETF (IYK) advanced by 0.1%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.8%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) rose by 1%.Ingredion (INGR) shares were up 0.8% pre-bell after the company said it has launched an all-cash tender offer to acquire Tate & Lyle, valuing the specialty ingredients company at about 3.7 billion British pounds ($5 billion).HealthcareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.2%, the Vanguard Health Care Index Fund (VHT) was down 0.2%, while the iShares US Healthcare ETF (IYH) slipped 0.2%. The iShares Biotechnology ETF (IBB) was 0.2% higher.Eli Lilly (LLY) stock was up more than 1% premarket after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.4% lower.Blackstone (BX) shares were up 0.4% pre-bell after closing Friday with a 2.7% fall. The Financial Times reported the company is preparing to offload more than $2 billion in private fund stakes through a structured bond deal.EnergyThe iShares US Energy ETF (IYE) was up 0.7%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.7%.Eni (E) stock was up nearly 1% before the opening bell, following a 1.1% decline in the prior trading session. Petronas and Eni said they have launched a new 50/50 joint venture called Searah that will combine businesses across Indonesia and Malaysia.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.9% to $91.33 per barrel on the New York Mercantile Exchange. Natural gas was down 2.9% to $3.13 per 1 million British Thermal Units. The United States Oil Fund (USO) advanced by 2%, while the United States Natural Gas Fund (UNG) was 2.4% lower.Gold futures for July retreated by 0.3% to $4,354.00 an ounce on the Comex. Silver futures declined by 0.7% to $68.60 an ounce. SPDR Gold Shares (GLD) was up by 0.2%, and the iShares Silver Trust (SLV) increased by 0.5%.
Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BX$E$EEM$EETH$EXI$FAS$FAZ$GHM$GLD$IBB$IGM$IGV$INGR$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LLY$NVDA$PMR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors
Sector Update: Healthcare Stocks Steady Pre-Bell Monday
Healthcare stocks were steady pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up a slight 0.1%.Tango Therapeutics (TNGX) shares were up more than 45% after the company said initial results from its phase 1/2 trial of vopimetostat in combination with Revolution Medicines' inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer.Eli Lilly (LLY) shares were up more than 2% after the company said additional phase 3 data showed that retatrutide achieved substantial weight loss with "meaningful" improvements in obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes.Shattuck Labs (STTK) said its phase 1 study of SL-325, a treatment for immune-related disease, showed good safety results and consistent drug performance in healthy volunteers. Shattuck Labs stock was up more than 14% premarket.
$IBB$LLY$STTK$TNGX$XLV
Showing 101-120 of 198
